Importantly, TMEV infection affects the differentiation of OPCs, showing a highly significant decrease in mature oligodendrocytes with myelinating capacity [ 23 ], something that in our case, was seen counteracted with by the administration of VP3.15.
← all excerpts
The Dual PDE7-GSK3β Inhibitor, VP3.15, as Neuroprotective Disease-Modifying Treatment in a Model of Primary Progressive Multiple Sclerosis.
1
—
—